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Introduction
Activation of a 1A -adrenoceptors (ARs) promotes downstream signalling cascades that are known to ameliorate pathological remodeling in heart failure, utilizing processes that include glucose uptake [41, 42] , receptor-mediated preconditioning, inhibition of cardiac cell death, and maintenance of myocyte contractility [18, 32] . The a 1A -AR subtype is robustly expressed in human ventricular cardiomyocytes and constitutes a potential drug target as it plays a dominant role in these processes, but the mechanisms involved are poorly characterised. In the present study we have investigated signalling pathways utilized by a 1A -ARs to stimulate glucose uptake, and show that activation of AMPK and mTOR has a key role.
The capacity of G protein-coupled receptors (GPCRs) to modulate mTOR activity is a newly emerging paradigm with the potential to link cell surface receptors with mTOR pathways involved in cell growth and survival. mTOR is a serine/threonine kinase and a member of the phosphatidylinositol 3-related kinase (PIKK) family that is essential for cell growth, metabolism, and energy homeostasis [23, 24, 35] . It forms two distinct multiprotein complexes: mTOR complex-1 (mTORC1) that regulates protein translation and cell growth, and mTOR complex-2 (mTORC2) that regulates actin cytoskeletal dynamics and cell survival. In mTORC1, the mTOR protein interacts with regulatory-associated protein of mTOR (Raptor), proline-rich Akt substrate of 40 kDa (PRAS40), mammalian lethal with SEC13 protein 8 (MLST8), DEP domain-containing mTORinteracting protein (DEPTOR), telomere maintenance 2 (Tel2), and Tel2-interacting protein 1 (TTI1), while mTORC2 comprises mTOR, rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated protein kinase interacting protein 1 (mSIN1), protein observed with Rictor 1 and 2 (Protor 1/2), MLST8, DEPTOR, Tel2 and TTI1. Clearly there are both common and distinct elements, however mTORC1 is most commonly defined by the presence of Raptor, while mTORC2 is characterised by association with Rictor. mTORC1 is required for embryonic cardiovascular development and for postnatal maintenance of cardiac structure and function, whereas mTORC2 is crucial to glucose homeostasis, as adipose-or skeletal muscle-specific ablation of rictor depresses insulin-stimulated glucose uptake in these tissues, and mice with either deficit display impaired glucose tolerance in vivo [21, 22] . We recently demonstrated that mTORC2 plays a pivotal role in b-AR mediated glucose uptake in skeletal muscle and brown adipocytes [33, 37] . A number of studies also suggest that mTORC2 is cardioprotective [12, 40, 47, 51] , and mice with cardiomyocyte-specific knockdown of rictor and consequent disruption of mTORC2 display cardiac abnormalities and exacerbated heart failure in response to pressure overload [49] . Following ischemic preconditioning, S6 ribosomal protein (S6RP) phosphorylation and activation of mTORC2 promote cardiomyocyte survival [39, 49] . Here we investigate the links between the Gaq/11-coupled a 1A -AR, mTOR signalling, glucose uptake and cell growth.
We show that activation of a 1A -AR in a CHO cell model system and in rat primary cardiomyocytes stimulates phosphorylation of mTORC1 and mTORC2, and promotes glucose uptake by parallel pathways involving AMPK and mTORC2. These findings provide a mechanistic understanding for the beneficial actions of a 1A -AR in cardiomyocytes.
Materials and methods

Materials
Cell culture media, antibiotics and supplements, Lipofectamine 2000, Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody and CellTracker TM Red CMTPX dye (Thermo Fisher Scientific, MA, USA); KCl, 5-Bromo-2-deoxyuridine (BrdU), bovine serum albumin, dithiothreitol, Dapi, Fluo-4-AM, insulin, A23187, phentolamine, noradrenaline, A61603, oxymetazoline, pertussis toxin, compound C, rapamycin, KU0063794 (Sigma, MO, USA); Akt inhibitor X (Merck Millipore, MA, USA); UBO-QIC; NF449 (Tocris Bioscience, Bristol, UK); siRNA (Qiagen, Hilden, Germany); Odyssey a 1A -AR and GLUT4 tagged with human c-myc epitope) were a gift from Dr. Kazuhiro Kishi (University of Tokushima, Tokushima, Japan). Cells were grown in 50:50 Dulbecco's modified Eagle's medium/Ham's F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS), glutamine (2 mM), penicillin (100 units/ml), and streptomycin (100 lg/ml) at 37°C with 5% CO 2 . After plating, cells were maintained in growth medium overnight, that was then substituted by serum-free medium and incubated for 40 h prior to experimentation.
Rat ventricular cardiomyocyte cultures
Hearts from 1-2-day-old Sprague Dawley rats were removed under aseptic conditions, the ventricles dissected and exposed to 0.1% trypsin (Life Technologies, NY, USA) in Hanks balanced salt solution (Sigma, MO, USA) at 4°C overnight. Trypsin was deactivated with high glucose Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and cells dissociated with type II collagenase treatment (2.5 mg/ventricle; Worthington Biochemical Corp., NJ) at 37°C in a shaking incubator for 10 min at 100 rpm, a total of four times. At the end of digestion, the dispersed cells were centrifuged for 5 min at 400g and collected into DMEM/10% FBS. Cells were then pre-plated on a 150 mm culture dish for 1 h at 37°C to remove fibroblasts. Nonadherent cells (myocytes) were transferred to another dish for another 1 h of pre-plating and counted using a hemocytometer, plated on 24-well and 96-well plates at 2.5 Â 10 5 cells/well and 3 Â 10 4 cells/well, respectively. Cells were incubated in DMEM/10%
FBS containing 100 mM 5-Bromo-2-deoxyuridine (BrdU; Sigma) overnight to reduce the proportion of proliferative cardiac fibroblasts. Cardiomyocytes were maintained in a humidified atmosphere at 5% CO 2 overnight. Cells were cultured in fresh DMEM/10% FBS for up to 5 days, then serum starved in DMEM/0% FBS or in medium containing 50 mM KCl overnight (Ca 2+ assays) prior to experimentation. For the studies described, a total of 50 neonatal rats were sacrificed using protocols approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee.
Whole cell [ 3 H]-prazosin radioligand binding assay
Whole-cell radioligand binding assays was performed as previously described [16] to determine the expression levels of a 1 -ARs. All experiments were performed at 37°C in 400 ll for 60 min.
NRVM were incubated with [ 3 H]-prazosin (0-5000 pM) using (À)-phentolamine (10 lM) to define non-specific binding. Cells were washed twice with ice-cold PBS, and digested with 0.4 M NaOH at 50°C for 1 h. The contents of each well were transferred to scintillation vials and scintillant (4 mL/vial) added. Samples were vortexed and incubated for 1 h at room temperature before radioactivity was measured using a Tri-Carb 2900TR Low Activity Liquid Scintillation Analyser (Perkin Elmer, Waltham, MA, USA). Total protein levels were determined in wells that had no radioligand added (Pierce TM BCA Protein Assay Kit; Thermo Fisher Scientific Inc., Rockford, IL, USA). All experiments were performed in duplicate with n as the number of independent experiments performed. ]i measurements expressed as a percentage of the response to calcimycin (A23187) (1 lM) in each experiment.
Measurement of intracellular free
Glucose uptake
Glucose uptake was measured as previously described [31] . IgG diluted at 1:5000 in blocking buffer) were added and incubated for 2 h at room temperature. Images were observed in the LI-COR Odyssey Ò Infrared Imaging System, and data were analyzed by the intensity of ratio between phospho and total protein using Image Studio Lite (LI-COR).
Transient transfection of siRNA-rictor and raptor
For transfection, CHO-K1 cells stably expressing the a 1A -AR were seeded at 1 Â 10 5 cells per well in 12-well plates and maintained in medium. siRNA constructs were obtained from QIAGEN. 100 nM of the rictor, raptor or control siRNA was transfected using Lipofectamine 2000 (Invitrogen). Immunoblotting and glucose uptake assays were performed 36 h after transfection. To confirm the efficacy of siRNAs, lysates from siRNA-treated cells were prepared for immunoblotting as above, resolved on 8% polyacrylamide gels, and transferred to PVDF membranes. Blots were blocked using 5% nonfat dry milk dissolved in TBS-T for 1 h and incubated overnight at 4°C with primary antibody for rictor or raptor (Cell Signalling) diluted 1:1000. Following washing, blots were probed with secondary antibody (HRP-linked anti-rabbit IgG, Cell Signalling) diluted 1:2000 and enhanced chemiluminescence (ECL, Amersham Biosciences).
Immunocytochemistry for detection of GLUT4 translocation
Cells were seeded at 5 Â 10 4 cells per well in 8-well culture chamber slides (BD Biosciences, Franklin Lakes, BJ) and maintained in medium. Medium was changed to serum-free medium and cells incubated overnight. Cells were treated with inhibitors for 30 min and stimulated with agonists for 2 h. Cells were fixed with 1% formaldehyde in PBS for 15 min, and quenched with 150 mM Tris pH 8.0 for 10 min. Cells were blocked for 1 h at room temperature with 5% BSA in PBS, then incubated with Myc-tag primary antibody solution (diluted 1:1000 in 1.5% BSA in PBS, Cell Signalling) overnight at 4°C followed by Alexa Fluor 488-conjugated goat antirabbit IgG secondary antibody (1:1000 dilution and 1.5% BSA in PBS) for 1 h. Images were observed in a Leica DMLB epifluorescence microscope (excitation 450-490 nm, dichroic mirror 510 nm, emission 515-535 nm). Images were acquired using a DC350F camera with IM500 software (Leica Microsystems AB). Content Imaging System (PerkinElmer).
Cell hypertrophy assay
Addition times and concentrations for inhibitor experiments
To test for the involvement of Gai/o proteins, cells were incubated with PTX (100 ng/ml) for 16 h prior to agonist addition. Otherwise, all inhibitors were added to the cells 30 min prior to agonist addition. Inhibitors and their targets were: UBO-QIC (100 nM, Gaq/11), NF449 (10 lM, Gas), Akt Inhibitor X (10 lM, Akt), Compound C (1 lM, AMPK), KU0063794 (1 lM, mTOR), and rapamycin (10 nM, mTORC1).
Data analysis
All measurements were taken in duplicate-quadruplicate with n referring to the number of independent experiments performed, and the results are expressed as the mean ± SEM. Data were analyzed using nonlinear curve-fitting (GraphPad Prism 6.0). [ 3 H]-prazosin saturation binding isotherms were analyzed via nonlinear regression using a one-site mass action model to derive estimates of dissociation constant (K D ) and maximal density of binding sites (B max ). Concentration-response curves were analyzed using the general equation for a sigmoid curve with a Hill slope of 1.0. The statistical significance of differences between groups was analyzed by one-or two-way analysis of variance (ANOVA), followed by post hoc Tukey multiple comparison tests when appropriate. Statistical significance was set at P < 0.05. Cell hypertrophy images were visualized and analyzed in an Operetta Ò High Content Imaging System (PerkinElmer, MA, USA). Cell areas were calculated from cytosol staining (Cell Tracker) divided by the number of nuclei (Dapi) to obtain the average cell area/cell. Between 2000 and 10,000 cells/ well were analyzed.
Results
a 1A -Adrenoceptor activation increases glucose uptake and GLUT4 translocation independently of Akt
Pathways involved in a 1A -AR-regulated glucose uptake were assessed in CHO-K1 cells stably co-expressing the human a 1A -AR and myc-tagged GLUT4 (CHOa 1A GLUT4myc cells). Based on whole cell binding with 3 H-prazosin, the a 1A -AR was expressed at 189 ± 19 fmol/mg protein (n = 8) in CHOa 1A GLUT4myc cells. Treatment of CHOa 1A GLUT4myc cells with insulin, noradrenaline, oxymetazoline, the a 1A -AR selective agonist A61603 or the calcium ionophore A23187 increased glucose uptake (Fig. 1A , Table 1 ). In CHOa 1A -GLUT4myc cells, maximum responses to NA, A61603, and oxymetazoline were higher than that of insulin (Table 1 ). In subsequent experiments, single concentrations of agonists were based on those that produced a near-maximal response for glucose uptake, and were insulin (100 nM), noradrenaline (100 nM), A61603 (10 nM), oxymetazoline (100 nM), and A23187 (1 mM). GLUT4 translocation examined by immunohistochemistry in nonpermeabilized CHOa 1A GLUT4myc cells, was increased by insulin, NA, A61603, oxymetazoline and A23187 (Fig. 1B and C) . As Akt is a key mediator of insulin-regulated translocation of GLUT4, we investigated Akt phosphorylation at Thr308 and Ser473. These sites were phosphorylated by insulin but intriguingly neither site was phosphorylated by a 1A -AR stimulation at any time point (Fig. 1D) . In accordance with these data, Akt inhibitor X (10 mM) significantly inhibited insulin-stimulated glucose uptake by 59%, but not a 1A -AR or Ca 2+ -mediated glucose uptake (Fig. 1E) . In CHOa 1A GLUT4myc cells, treatment with noradrenaline, A61603, oxymetazoline, or A23187 but not insulin increased Ca 2+ release ( Fig. 2A, Table 1 ). The Gaq/11 inhibitor UBO-QIC (100 nM) abolished noradrenaline, A61603, and oxymetazolineinduced Ca 2+ release in CHOa 1A GLUT4myc cells (Fig. 2B ). Glucose uptake in response to noradrenaline, A61603, and oxymetazoline was substantially inhibited by UBO-QIC whereas the Gas inhibitor NF449 and Gai/o inhibitor PTX (100 ng/ml) had no effect on glucose uptake in response to all agonists ( Fig. 2C-E) . In CHOa 1A -GLUT4myc cells, noradrenaline, A61603, oxymetazoline, and A23187 caused phosphorylation of AMPK at Thr172 (Fig. 2F ) that was inhibited by the AMPK inhibitor Compound C (Comp C, 1 mM) (Fig. 2G ). Compound C (1 mM) partially but significantly inhibited glucose uptake in response to noradrenaline, A61603, oxymetazoline and the Ca 2+ ionophore A23187 by 71%, 59%, 68%, and 98% respectively, but not in response to insulin (Fig. 2H) suggesting the involvement of the Ca 2+ -AMPK pathway in a 1A -ARmediated glucose uptake. GLUT4 translocation increased by noradrenaline, A61603, oxymetazoline, and A23187 was inhibited by Compound C (1 mM) in non-permeabilized CHOa 1A GLUT4myc cells (Fig. 2I ).
3.3. The role of mTORC2 in a 1A -Adrenoceptor mediated glucose uptake
Our previous study indicated that mTOR Complex 2 (mTORC2) has a significant role in insulin and b 2 -AR-mediated glucose uptake in L6 rat skeletal muscle cells [37] . To determine whether mTOR is involved in insulin-and a 1A -AR mediated glucose uptake, we tested the effect of the mTORC1 inhibitor rapamycin (10 nM) or dual mTORC1/2 inhibitor KU0063794 (1 mM) (Fig. 3A) . The inhibition by KU0063794 and lack of inhibition by rapamycin indicates a role for mTORC2 rather than mTORC1, and glucose uptake in response to insulin, noradrenaline, A61603, and oxymetazoline was inhibited by 115%, 73%, 68%, and 69% respectively by KU0063794 (Fig. 3A) . We also utilized siRNAs in CHOa 1A -GLUT4myc cells to selectively knock down the mTORC1-associated protein raptor or the mTORC2-associated protein rictor. Control scrambled siRNAs had no effect on either raptor or rictor protein expression whereas the siRNAs for rictor and raptor caused selective knockdown of the respective proteins (Fig. 3B) . Raptor knockdown did not affect glucose uptake, whereas rictor knockdown significantly decreased glucose uptake in response to insulin, noradrenaline, A61603 or oxymetazoline, by 93%, 73%, 57%, and 64% respectively (Fig. 3B) . Knockdown of raptor or rictor had no effect on A23187-mediated glucose uptake indicating that mTOR is not downstream of Ca 2+ for glucose uptake (Fig. 3B) . Phosphorylation of mTOR at Ser2481 is characteristic of mTORC2 and was significantly increased by insulin, noradrenaline, A61603, and oxymetazoline ( Fig. 3C) , and markedly inhibited by KU0063794 (1 mM) in CHOa 1A GLUT4myc cells (Fig. 3D ). GLUT4 translocation in non-permeabilized CHOa 1A GLUT4myc cells in response to insulin, noradrenaline, A61603, oxymetazoline but not A23187 was inhibited by KU0063794 (1 mM), (Fig. 3E ). p-NDRG1 (Thr346) is an effector in the mTORC2/SGK1 pathway and is often used as a downstream marker of mTORC2 activity. Insulin, noradrenaline, A61603, oxymetazoline, but not A23187 increased p-NDRG1 (Thr346), suggesting that Ca 2+ is not an upstream regulator of mTORC2 (Fig. 3F) . p-NDRG1 (Thr346) in response to insulin, noradrenaline, A61603, and oxymetazoline was markedly inhibited by KU0063794 (1 mM), confirming that NDRG1 is a downstream target of mTOR (Fig. 3G) . To investigate possible mTOR and AMPK crosstalk, p-mTOR at Ser2481 and p-AMPK at Thr172 were measured in the presence of Compound C or KU0063794 respectively. p-mTOR (Ser2481) was stimulated by insulin and all a 1 -AR agonists, and not blocked by Compound C (1 lM, Fig. 3H ). Furthermore, KU0063794 (1 lM) had no effect on AMPK phosphorylation at Thr172 stimulated by noradrenaline (NA), A61603, oxymetazoline, and A23187 (Fig. 3I ). These experiments demonstrate that mTOR activation and AMPK phosphorylation in response to a 1A -AR agonists occurs by pathways that operate independently of each other. Phosphorylation of mTOR at Ser2481 is characteristic of mTORC2, while mTORC1 is phosphorylated predominantly at Ser2448 [4] . The latter, indicative of mTORC1, occurred in CHOa 1A -GLUT4myc cells in response to insulin, noradrenaline, A61603, oxymetazoline, and A23187 (Fig. 4A) . In addition, S6rp, an established downstream marker of mTORC1 activity and protein synthesis, was phosphorylated at Ser235/236 by all agonists (Fig. 4B) . The mTORC1 inhibitor rapamycin (10 nM) decreased basal and agonist stimulated S6rp phosphorylation (Fig. 4C) , suggesting that the mTOR-S6rp pathway is distinct from the pathway stimulating glucose uptake, since rapamycin had no effects on insulin or a 1A -AR mediated glucose uptake (Fig. 3A) . To investigate a validated functional outcome of mTORC1 activation, we measured the capacity of a 1A -AR agonists to induce cellular hypertrophy. Long-term treatment (48 h) with A61603 and oxymetazoline, but not insulin, significantly increased cell surface area (Fig. 4D) . Hypertrophy was inhibited by the addition of the selective a 1A -AR antagonist tamsulosin (10 nM) or KU0063794 (1 mM), suggesting that a 1A -ARs stimulate hypertrophy via mTOR in CHOa 1A GLUT4myc cells (Fig. 4E and F) . Table 1 ). In subsequent experiments, single concentrations of agonists were used based on a near-maximal response for glucose uptake, and were insulin (1 mM), noradrenaline (1 mM), A61603 (100 nM), oxymetazoline (1 mM), and A23187 (1 mM). In NRVM, treatment with noradrenaline, A61603, or A23187 but not insulin or oxymetazoline increased Ca 2+ release (Fig. 5B , Table 1 ). Interestingly, although oxymetazoline did not increase Ca
2+
, it did increase glucose uptake ( Fig. 5A and B) . The a 1 -AR antagonist prazosin (100 nM) and selective a 1A -AR antagonist tamsulosin (10 nM) inhibited noradrenaline, A61603, and oxymetazoline mediated glucose uptake in NRVM (Fig. 5C ). The Gaq/11 inhibitor UBO-QIC (UBO, 100 nM) substantially inhibited noradrenaline, A61603, and oxymetazoline-induced glucose uptake in NRVM by 55%, 77%, and 77% respectively (Fig. 5D ). Since Akt is a key mediator of insulin-stimulated GLUT4 translocation and glucose uptake, we investigated Akt phosphorylation at Thr308 and Ser473. These sites were phosphorylated following insulin treatment, but not by a 1 -AR stimulation ( Fig. 5E and F) .
3.6. The pattern of a 1 -adrenoceptor activation of glucose uptake, signalling and cell hypertrophy is replicated in rat primary ventricular myocytes
As with Ca 2+ release, noradrenaline, A61603, and A23187 caused phosphorylation of AMPK at Thr172 that was inhibited by the AMPK inhibitor Compound C (Comp C, 1 mM) in NRVM (Fig. 6A) . mTOR phosphorylation at Ser2448 was increased by all agonists, and mTOR Ser2481 was phosphorylated by insulin, noradrenaline, A61603, and oxymetazoline, and phosphorylation was blocked by KU0063794 (1 mM) (Fig. 6A) . In NRVM, glucose uptake in response to insulin, noradrenaline, A61603, and oxymetazoline was inhibited by the mTORC1/2 inhibitor KU0063794 (1 mM) by 72%, 62%, 59%, and 69% respectively whereas the mTORC1 inhibitor rapamycin (10 nM) had no effect, again suggesting the involvement of mTORC2 in glucose uptake (Fig. 6B ). Compound C (1 mM) partially inhibited glucose uptake in response to noradrenaline, A61603, and A23187 by 53%, 48%, and 68% respectively, in accord with AMPK phosphorylation in response to these agonists (Fig. 6C) . It has been reported that Compound C has inhibitory activity at other kinases, including mTOR and PI3K. Our data in NRVM confirm that at the 1 lM concentration we used, the effects of Compound C are consistent with a primary action at AMPK. Unlike in the CHOa 1A GLUT4myc cells, Compound C does not inhibit oxymetazoline-mediated glucose uptake in NRVM (Fig. 6C) , and is blocked by Compound C (Fig. 6C ) but unaffected by inhibitors of mTOR (Fig. 6B) .
Combined blockade of AMPK with Compound C (1 mM) and of mTOR by KU0063794 (1 mM) abolished glucose uptake in response to all agonists in NRVM (Fig. 6C) by 90% (insulin), 100% (noradrenaline), 99% (A61603), 87% (oxymetazoline), and 88% (A23187) respectively, suggesting that glucose uptake in response Fig. 4 . a 1A -adrenoceptor stimulation activates mTORC1 and hypertrophy in CHOa 1A GLUT4myc cells Phosphorylation of mTOR Ser2448 (n = 5) (A) or S6rp Ser235/236 (n = 6) (B) stimulated by insulin (100 nM), noradrenaline (100 nM), A61603 (10 nM), oxymetazoline (100 nM), and A23187 (1 mM) for 5, 10, 30, 60, or 120 mins in CHOa 1A GLUT4myc cells. (C) The effect of mTORC1 inhibitor rapamycin (10 nM) on S6rp Ser235/236 phosphorylation in response to insulin (100 nM), noradrenaline (100 nM), A61603 (10 nM), oxymetazoline (100 nM), and A23187 (1 mM) at 120 min time point in CHOa 1A GLUT4myc cells (n = 5). (D) Cell surface areas were calculated using the Operetta High-Content Imaging System. The average lm 2 /cell was increased following the treatment of A61603 or oxymetazoline for 48 h (n = 5). (E) The a 1A -AR antagonist tamsulosin (10 nM) and mTOR inhibitor KU0063794 (1 mM) significantly inhibited A61603 (10 nM) or oxymetazoline (100 nM) mediated increase of cell surface areas (n = 4). (F) Images of CHOa 1A GLUT4myc cells after 48 h treatment of insulin (100 nM), A61603 (10 nM), and oxymetazoline (100 nM) in the presence or absence of the a 1A -AR selective antagonist tamsulosin (10 nM) and KU0063794 (1 mM). Nuclei were visualized with DAPI and cytosol was stained with CellTracker. Each value represents the mean ± SEM. *P < .05. **P < .01. ***P < .001.
to a 1 -AR agonists involves both pathways and they operate in parallel rather than sequentially. This was confirmed by measurement of AMPK (Thr172) and mTOR (Ser2448, Ser2481) phosphorylation, which were not inhibited by KU0063794 (1 mM) or Compound C (1 mM) respectively (Fig. 6D) . In NRVM, insulin, noradrenaline, and A61603 increased S6RP phosphorylation (Ser235/236), a downstream target of mTORC1 (Fig. 6E) , and it was inhibited by rapamycin (10 nM) (Fig. 6F) . 48 h treatment of NRVM with the a 1A -AR agonists A61603 and oxymetazoline significantly increased cell surface area that was reduced by KU0063794 (100 nM) by 60% and 102% respectively ( Fig. 6G and H) . These results suggest that a 1 -ARs stimulate three distinct signalling pathways with AMPK and mTORC2 promoting glucose uptake and mTORC1 stimulating protein synthesis (Fig. 7) .
Discussion
The present studies show that activation of a 1 -AR in cells stably co-expressing the human a 1A -AR and myc-tagged GLUT4 (CHOa 1A -GLUT4myc cells) stimulates phosphorylation of mTORC1 and mTORC2, and promotes glucose uptake by parallel pathways involving AMPK and mTORC2 and that this pattern of signalling is replicated in rat primary ventricular cardiomyocytes. These findings suggest mechanisms that could underpin the beneficial effects of activating the a 1A -AR in conditions such as cardiac failure. a 1 -ARs classically signal through Gaq/11 to activate phospholipase C (PLC), causing hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (Fig. 7) . DAG activates protein kinase C (PKC) [34, 45] whereas IP3 activates IP3 receptors to release Ca 2+ , that in the heart promotes positive inotropism and hypertrophy [38] .
Earlier studies have suggested connections between a 1A -ARs and mTORC1 [44] , and the a 1A -AR subtype-selective agonist A61603
has been shown to promote hypertrophy of cultured cardiomyocytes, increased protein synthesis, cell size, and expression of atrial natriuretic factor (Nppa) [2] . In addition, the non-selective a 1 -AR agonist phenylephrine promotes mTORC1-dependent hypertrophic responses that are blocked by rapamycin [13, 43] .
These results are consistent with our findings that the a 1A -AR promotes mTOR phosphorylation at Ser2448, S6rp phosphorylation and hypertrophy (Fig. 4) , all characteristic of mTORC1 activation [10] . It was of interest that this occurred despite simultaneous activation of AMPK, as under conditions of ATP deprivation, increased AMPK activity suppresses mTORC1 due to phosphorylation of TSC2 and inhibition of Rheb [29] . Furthermore, we did not see positive or negative effects of Compound C on mTOR phosphorylation at Ser2448 (Fig. 6D) . These findings will require further investigation but may reflect distinct characteristics of a 1A -AR signalling, such as responses occurring within specific cellular compartments or protein complexes, or simply that a 1A -AR-mTORC1 activation overcomes the inhibitory effects of AMPK.
In skeletal muscle, a 1 -AR stimulated glucose uptake occurs downstream of Ca 2+ release, utilizing calmodulin-dependent protein kinase kinase (CaMKK) and 5 0 adenosine monophosphateactivated protein kinase (AMPK) (Fig. 7) [15, 48] . The role of mTORC2 in glucose uptake was later discovered [21] . Glucose uptake mediated by b-ARs in skeletal muscle involves activation of mTORC2 and GLUT4 translocation [33, 37] . This signalling pathway involves activation of adenylyl cyclase, increased cAMP levels, activation of PKA with phosphorylation of mTORC2 at Ser2481 [37] . Although glucose uptake in response to insulin also involves (1 mM) in NRVM (n = 5). p-, phosphorylated. Each value represents the mean ± SEM. *P < .05. **P < .01. ***P < .001.
phosphorylation of mTORC2, the b-AR pathway differs from that of insulin in that it does not involve Akt and PIP 3 [37] . Activation of the insulin receptor and IRS proteins causes stimulation of PI-3-kinase, increasing PIP 3 that recruits inactive Akt and PDK1 to the plasma membrane. This facilitates PDK1-mediated phosphorylation of Akt at Thr308, causing a conformational change required for phosphorylation at Ser473 and full activation, leading to phosphorylation of AS160 and translocation of GLUT4 to the plasma membrane. We show here in CHOa 1A GLUT4myc cells and cardiomyocytes that a 1A -ARs activate mTORC2 in a PI-3-kinase/Akt independent manner, in parallel with Ca 2+ activation of AMPK to cause GLUT4 translocation and glucose uptake. Both processes involve coupling of the a 1A -AR to Gaq/11. Importantly blockade of both AMPK and mTOR was required to completely inhibit glucose uptake in response to a 1 -AR agonists. In agreement with activation of parallel AMPK and mTORC2 signalling, glucose uptake can still be observed when only one of the pathways is activated, namely treatment of cells with the Ca 2+ ionophore A23187, or in cardiomyocytes, treatment with the partial agonist oxymetazoline that stimulates mTORC2 but not Ca 2+ release or AMPK activation. (H) Images of NRVM after 48 h treatment of insulin (1 mM), A61603 (100 nM), and oxymetazoline (1 mM) in the presence or absence of KU0063794 (1 mM). Nuclei were visualized with DAPI and cytosol was stained with CellTracker. p-, phosphorylated. Each value represents the mean ± SEM. *P < .05. **P < .01. ***P < .001.
There is extensive evidence that a 1 -ARs have important roles in modulating hypertrophy and other protective effects in heart failure [32] . The a 1A -AR subtype plays a dominant role in these processes, so that cardiomyocytes from a 1A/1B -AR double knockout mice show markedly increased sensitivity to pro-apoptotic stimuli, and are rescued by expression of a 1A -but not a 1B-ARs [14] . a 1A -AR also most likely contribute to ischemic preconditioning [18, 50] .
Activation or overexpression of the a 1A -AR maintains myocyte contractility whereas the a 1B -AR has a negative effect [6, 7, 26, 36] .
Two recent studies highlight directly the potential utility of activation of a 1A -ARs in cardioprotection. Chronic (1 week) treatment of mice with low dose A61603 caused a reduction of polyunsaturated fatty acids and endocannabinoids, well recognised mediators of inflammation [46] , and oral administration (twice daily for 1 week) of an orally active selective a 1A -AR agonist Dabuzalgron, developed as a treatment for urinary incontinence, was protective against doxorubicin-induced cardiotoxicity [3] . The a 1A -AR agonist rescued pathways associated with mitochondrial function including complex I, cytochrome C oxidase and ATP-synthase and maintained myocardial ATP levels [3] . A key pathway involved in the cardioprotective effect was ERK1/2 shown to be activated following a 1A -AR activation [3] . Our findings presented here in a CHO cell system and in cardiomyocytes would suggest that activation of mTORC2 and glucose uptake, both mechanisms that are known to be protective in cardiac failure, may also contribute to the cardioprotection observed with a 1A -AR agonists. Taken together there is a case that the use of a 1A -AR agonists improves function in cardiac failure.
Glucose uptake and utilization are critical for cardiac energy production, particularly in the failing heart [20] . The normal adult heart derives ATP primarily from fatty acid oxidation, but displays metabolic flexibility reliant upon complex regulation at a transcriptional, post-translational and metabolic level [17] . Switching fully to glucose as the primary fuel can be maladaptive as there is insufficient ATP generation to support contraction [30] , whereas augmentation by glucose uptake is beneficial. For example, mice with transgenic overexpression of cardiac GLUT1 are protected from contractile dysfunction induced by chronic pressure overload [25] , and GLUT1 overexpression restores contractile efficiency in mice with defective fatty acid oxidation [27] . Intrinsic glucose metabolism limits contractile function during heart failure [1] , and since this is likely exacerbated by cardiac insulin resistance, the capacity of a 1A -AR agonists to promote insulin-independent glucose uptake could provide an important therapeutic avenue. In cardiac failure increases in circulating catecholamines cause large increases in demand for energy and hence glucose. As outlined above, the improved glucose uptake in response to activation of a 1A -AR may be beneficial in meeting these increased energy demands. In cardiac ischemia it has been suggested that glucose uptake provides an important energy source and protects against injury [41, 42] .
In cardiomyocytes, oxymetazoline promoted robust glucose uptake, with an E max similar to those of A61603 and insulin, but was unable to stimulate Ca 2+ release (Fig. 5 ). In addition, glucose uptake in response to oxymetazoline (and insulin) was not suppressed by the AMPK inhibitor Compound C whereas both were inhibited by KU0063794, suggesting the involvement of mTOR but not the Ca 2+ -CaMKK-AMPK pathway. The other two agonists displayed a higher (NA) or equivalent (A61603) potency for Ca 2+ release compared to glucose uptake in NRVM (Table 1) , and glucose uptake was inhibited by Compound C (Fig. 6) . The difference between oxymetazoline, A61603 and noradrenaline was of interest since we have previously shown that oxymetazoline displays a biased signalling profile at a 1A -AR [8] . This biased agonism or functional selectivity refers to the ability of some agonists acting at a 1A -ARs to selectively activate particular signalling pathways [9, 19, 28] . Biased agonists that promote beneficial cellular responses but not detrimental effects are considered to have great therapeutic promise. Apparent biased agonism may be associated with off-target effects [5] , but our data indicated that oxymetazoline promotes glucose uptake by activating the a 1A -AR in cardiomyocytes. Like A61603, oxymetazoline-stimulated glucose uptake was blocked by the selective a 1A -AR antagonist tamsulosin as well as prazosin (Fig. 5C ). This excludes a contribution from a 1B -ARs, and in combination with inhibition by UBO-QIC, any effect of the Gai/o-coupled a 2A -AR for which oxymetazoline also has high affinity. Although UBO-QIC acts as an inhibitor of both Gaq/11 and Gbc signalling at the concentration used here, inhibition of Gbc signalling has been demonstrated only for responses mediated by Gai/o-coupled receptors including the A1 adenosine receptor and the M2 acetylcholine receptor [11] . Pleiotropic coupling of the a 1A -AR to Gai/o and a resulting release of Gbc can also be excluded, as glucose uptake in CHOa 1A GLUT4myc cells expressing only this receptor is not affected by PTX treatment. As outlined above, biased agonism results most commonly from preferential coupling to different upstream effectors, yet the UBO-QIC data indicate that A61603, NA and oxymetazoline share Gaq/11 as a common effector for glucose uptake (Fig. 2C) . One possible explanation is that coupling between a 1A -ARs and Gaq/11, and the resulting stabilization of the receptor active state, represents an obligatory step in receptor interaction with distinct effector(s) involved in mTOR-mediated glucose uptake. The cardioprotective role of the mTORC2 signalling complex has been identified only recently. We have now discovered that mTORC2 is activated by a 1A -ARs both in a CHO cell model system and in primary cardiomyocytes, and have thus identified a new upstream initiator of this important survival pathway. Our demonstration that glucose uptake in cardiomyocytes is stimulated by the 
